SCHOTT Pharma (1SXP) investor relations material

Executive summary

• Q1 2026 revenue rose 4.8% at constant currencies to EUR 240 million, driven by strong demand for high-value solutions (HVS), which increased their revenue share to 57%, up 2 percentage points year-over-year.

• EBITDA increased by 11.1% to EUR 65 million, with margin improving to 27.1%, supported by HVS and especially drug containment solutions.

• Net income rose 12% to EUR 33.3 million, with earnings per share up to EUR 0.22.

• Innovations included the launch of EVERIC lyo amber vials for light-sensitive biologics and new ISO-compliant sterile polymer cartridges.

• Strategy focuses on expanding HVS, innovation, and aligning with pharma industry trends.

Financial highlights

• Revenue for Q1 2026 was EUR 240.2 million, up 3.8% year-over-year (4.8% at constant currencies), mainly due to strong HVS performance.

• Group EBITDA rose 11.1% to EUR 65.2 million, margin expanded from 25.4% to 27.1%.

• EBIT increased by 9% to EUR 43.8 million; net income reached EUR 33.3 million, up 12% year-over-year; EPS was EUR 0.22.

• Free cash flow was EUR -20 million, impacted by a deferred customer payment; capital expenditure reached EUR 23.4 million.

• Equity ratio improved to 57.3% from 55.9% at the prior year-end.

Outlook and guidance

• FY 2026 guidance confirmed: organic revenue growth of 2%–5% at constant currencies, EBITDA margin around 27%, and CAPEX of EUR 140–160 million.

• HVS revenue share expected to remain robust at 57%.

• Tax rate for the year assumed at approximately 22%.

• Guidance assumes stable exchange rates and no major disruptions.